Funds similar to Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct-Growth in the Equity: Sectoral-Pharma category include Nippon India Pharma Fund Direct-Growth, ICICI Prudential Healthcare Fund Direct-Growth, and SBI Healthcare Opportunities Fund Direct Plan-Growth. These funds follow a comparable investment mandate and are benchmarked against similar indices. You can compare them in detail — across returns, risk metrics, expense ratio, and portfolio composition — using the fund comparison tool on sharpely.

On a 3-year return basis Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct-Growth is ranked 12 out of 11 funds in the Equity: Sectoral-Pharma category as of 4 Sep 2026. On a 5-year return basis it ranks 9 out of 8. Consistently ranking in the top across multiple time periods is a stronger signal of fund quality than a single-period rank.

Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct-Growth has an expense ratio of 0.55%. The peers Nippon India Pharma Fund Direct-Growth has an expense ratio of 0.99% and ICICI Prudential Healthcare Fund Direct-Growth has 1.31%. Over the long term, a higher expense ratio can meaningfully drag on returns, so it is worth evaluating whether the fund's performance justifies the additional cost.

Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct-Growth has an AUM of ₹195.49 crore. The peers Nippon India Pharma Fund Direct-Growth has an AUM of ₹9,279.11 crore and ICICI Prudential Healthcare Fund Direct-Growth has ₹6,802.61 crore. A large AUM can sometimes limit a fund's ability to take meaningful positions in mid and small-cap stocks, as larger trades can move prices. This is particularly relevant for funds that invest outside large caps.

The top performing fund in the Equity: Sectoral-Pharma category on a 3-year basis is UTI Healthcare Fund Direct-Growth with a CAGR of 24.47% as of 4 Sep 2026. Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct-Growth has delivered 19.84% CAGR over the same period, ranking 12 out of 11 funds. You can view and compare the full category ranking on sharpely.

On a risk-adjusted basis, Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct-Growth has a Sharpe ratio of 1.14 compared to the Equity: Sectoral-Pharma average of 1.04 as of 4 Sep 2026. It ranks 3 out of 13 funds in its category on Sharpe ratio.